上海景峰制药

Shanghai Jingfeng Pharmaceutical is a core subsidiary of Hunan Jingfeng Pharmaceutical, specializing in the R&D and manufacturing of high-end injectable pharmaceuticals. The company is a market leader in China for sodium hyaluronate injections, which are primarily used for the treatment of osteoarthritis and joint-related conditions. Its product portfolio spans multiple therapeutic areas, including cardiovascular health, oncology, and gynecology, with a focus on both chemical generics and biological products. Shanghai Jingfeng operates advanced GMP-certified production lines and maintains a strong presence in the domestic Chinese healthcare market. The company is recognized for its expertise in injectable formulation and large-scale production of specialized treatments.